Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul 1;32(4):331-337.
doi: 10.1097/ICU.0000000000000767.

Advances in corneal graft rejection

Jia Yin  1
Affiliations
Review

Advances in corneal graft rejection

Jia Yin. Curr Opin Ophthalmol. .

Abstract

Purpose of review: Immune rejection after corneal transplantation is a major risk for graft failure. We aim to summarize recent advances in the understanding and management of graft rejection.

Recent findings: Immune rejection remains the leading cause of graft failure in penetrating keratoplasty (PKP). While ABO blood type and sex match between donor and recipient may reduce rejection, human leucocyte antigens class II matching in a randomized study did not reduce the risk of rejection in high-risk PKP. Compared with PKP, deep anterior lamellar keratoplasty, descemet stripping automated endothelial keratoplasty, and descemet membrane endothelial keratoplasty have lower immune rejection rates of 1.7-13%, 5-11.4%, and 1.7-2.8%, respectively, based on long-term (5 years and more) studies. Whether immune rejection is a major risk factor for graft failure in these lamellar keratoplasties is unclear. While there have not been major advances in the systemic management of graft rejection, topical nonsteroid agents such as tacrolimus and anti-vascular endothelial growth factor have shown promise in high-risk cases.

Summary: Immune rejection remains the leading cause of graft failure in PKP. Lamellar keratoplasties have significantly lower rejection rates compared with PKP. The significance of rejection in the failure of lamellar grafts warrants further investigation.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest

No relevant conflict of interests to declare.

References

    1. Armitage WJ, Goodchild C, Griffin MD, et al.. High-risk corneal transplantation: recent developments and future possibilities. Transplantation 2019; 103:2468–2478. - PMC - PubMed

    2. The review article highlights critical research areas in the understanding and promotion of high-risk corneal transplants.

    1. Jabbehdari S, Rafii AB, Yazdanpanah G, et al. Update on the management of high-risk penetrating keratoplasty. Curr Ophthalmol Rep 2017; 5:38–48. - PMC - PubMed
    1. Di Zazzo A, Kheirkhah A, Abud TB, et al. Management of high-risk corneal transplantation. Surv Ophthalmol 2017; 62:816–827. - PMC - PubMed
    1. Azevedo Magalhaes O, Shalaby Bardan A, Zarei-Ghanavati M, Liu C. Literature review and suggested protocol for prevention and treatment of corneal graft rejection. Eye (Lond) 2020; 34:442–450. - PMC - PubMed

    2. The article provides a management protocol (algorithm) for various types of corneal transplantation.

    1. Alio JL, Montesel A, El Sayyad F, et al. Corneal graft failure: an update. Br J Ophthalmol 2020. - PubMed

    2. The article provides a comprehensive summary in table format of long-term and mid-term outcomes of penetrating keratoplasty, deep anterior lamellar keratoplasty, and DSAEK.